1. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230–41.
2. Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics, safety, and overall response rate achieved with subcutaneous administration of rituximab in combination with chemotherapy were comparable with those achieved with intravenous administration in patients with folicular lymphoma in the first-line setting: Stage 1 results of the phase 3 SABRINA study (BO22334). Cancer Research UK Centre.
3. Hoffmann-La Roche (data on file) 2011.
4. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84.
5. Griffin MM, Morley N. Rituximab in the treatment of non-Hodgkin’s lymphoma – a critical evaluation of randomized controlled trials. Expert Opin Biol Ther 2013;13:803–11.
6. Haller MF. Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Tech 2007;10:861–4.
7. Halozyme Therapeutics. Prescribing information: Hylenex recombinant (hyaluronidase human injection) 150 USP units/ml, single dose vial. Initial U.S. approval 2005.
8. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012;13:869–78.
9. Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos 2013;41:248–55.
10. Kagan L, Turner MR, Balu-Iyer SV, et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012;29:490–9.
11. Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulations of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012;3:117–24.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer; Version I.2012 www.nccn.org (Zugriff am 11. Februar 2012).
13. Pivot X, Gligorow J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013;14:962–70.
14. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
15. Wynne C, Vernon H, Schwabe C, et al. Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2012;20:1–10.
Dr. Hans-Peter Lipp, Apotheke des Universitätsklinikums Tübingen, Röntgenweg 9, 72076 Tübingen, E-Mail: Hans-Peter.Lipp@med.uni-tuebingen.de